Erratum to ‘Maternal BCG primes for enhanced health benefits in the newborn’ [Journal of Infection Volume 84, Issue 3 (2022) 321-328]

Open AccessPublished:September 01, 2022DOI:
      The publisher regrets the supplementary tables were not included in the article and the online links for the supplementary tables incorrectly redirected readers to Table 1 and Table 2.
      The publisher would like to apologise for any inconvenience caused.

      Linked Article

      • Maternal BCG primes for enhanced health benefits in the newborn
        Journal of InfectionVol. 84Issue 3
        • Preview
          The early-life mortality remains high in developing countries and nearly half of under-5 deaths occur in the neonatal period.1 Neonatal sepsis caused by a range of different bacterial agents, against which specific vaccines are not available, is a leading cause of death.2 A strategy to reduce early-life infection severity is the at-birth provision of live vaccines such as Oral Polio Vaccine (OPV) and Bacille Calmette-Guérin (BCG).3 In a series of randomized controlled trials (RCTs) conducted by the Bandim Health Project (BHP, ) in Guinea-Bissau, BCG provided at hospital discharge a few days after birth reduced infectious disease mortality risk by 40% (95% Confidence Interval (CI): 11–60%)4, particularly due to protection against neonatal sepsis.
        • Full-Text
        • PDF
        Open Access